Why is the microbiology lab calling about an extended-spectrum beta-lactamase bacterium from a wound culture?

Orthopedics

Volumn 28, Issue 11, 2005, Pages 1322-1325

  Ribes, Julie ^a   Rapp, Robert P ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; AZTREONAM; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CILASTATIN; IMIPENEM; MEROPENEM; MONOBACTAM; PENICILLIN G; PIPERACILLIN; THIOL DERIVATIVE; TICARCILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL MUTATION; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM ISOLATION; CLINICAL PRACTICE; DRUG HYDROLYSIS; DRUG MECHANISM; ENZYME STRUCTURE; ENZYME SYNTHESIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; KLEBSIELLA PNEUMONIAE; MEDICAL SPECIALIST; NONHUMAN; OUTCOMES RESEARCH; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; STRUCTURE ANALYSIS; WOUND INFECTION;

BACTERIA; BETA-LACTAMASES; ESCHERICHIA COLI; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; SEPSIS; SURGICAL WOUND INFECTION;

EID: 28244467392     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Anon. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control. 2003. 31:481-498.
2. Rice L. Evolution and clinical importance of extended-spectrum, beta-lactamases. Chest. 2001; 119(suppl 2):391s-396s.
3. Danziger LH, Pendland SL. Bacterial resistance to beta-lactam antibiotics. Am J Health Syst Pharm. 1995; 52(suppl 6):s3-s8.
4. Chaves J, Ladona MG, Segura C, et al. SHV-1 beta-lactamase is mainly a chromosomally encoded species specific enzyme in Klebsiella pneumoniae, Antimicrob Agents Chemother. 2001; 45:2856-2861.
5. Liu PY, Hall GD, Livermore DM. Survey of the prevalence of beta-lactamases amongst 1000 gram-negative bacilli isolated consecutively at the Royal London Hospital. J Antimicrob Chemother. 1992; 30:429-447.
6. Cheng AF, Ling TK, Lam AW, Fung KS, Wise R. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents. J Antimicrobial Chemother. 1993; 31:699-709.
7. Woodcock JM, Andrews JM, Brenwald NP, Ashby JP, Wise R. The in-vitro activity of faropenem, a novel oral penem. J Antimicrobial Chemother 1997; 39:35-43.
8. Amyes SG, Miles RS. Extended-spectrum beta-lactamases: the role of inhibitors in therapy. J Antimicrobial Chemother 1998; 42:415-417.
9. Paterson DL, Wen-Chien K, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: Implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med. 2004; 140;26-32.
10. Burgess DS, Hall RG II, Lewis JS II. Jorgensen JH, Patterson JE. Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2 year period. Pharmacotherapy. 2003; 23:1232-1237.
11. Clinical and Laboratory Standards Institute (NCCLS). Performance standards for antimicrobial susceptibility testing: Fourteenth informational supplement. NCCLS document M100-S14. Table 2A (disk diffusion and MIC). Available at: http://www.nccls.org/template.cfm?template.=/search/SearchDisplay.cfm. Accessed May 1, 2005.
12. Clinical and Laboratory Standards Institute (NCCLS). Performance standards for antimicrobial susceptibility testing: Fifteenth informational supplement. CLSI/NCCLS document M100-S15. Table 2A (disk diffusion and MIC). Available at: http://www.nccls.org/template.cfm?template.=/search/Search-Display.cfm. Accessed May 1, 2005.
13. Thompson KS. Controversies about extended spectrum and AmpC beta-lactamases. Emerg Infect Dis. 2001; 7:333-336.
14. Pitout JD, Reisbig MD, Venter EC, Church DL, Hanson ND. Modification of the double-disk test for detection of Enterobacteriaceae producing extended-spectrum and AmpC beta-lactamases. J Clin Microbiol. 2003; 41:3933-3935.
15. Marchandin H, Carriere C, Sirot D, Pierre HJ, Darbas H. TEM-24 produced by four different species of Enterobacteriaceae, including Providencia rettgeri, in a single patient. Antimicrob Agents Chemother 1999; 43:2069-2073.
16. Mugnier P, Dubrous P, Casin I, Arlet G, Collatz E. A TEM-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1996; 40:2488-2493.
17. Steward CD, Rasheed JK, Hubert SK, et al. Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods. J Clin Microbiol. 2001; 39:2864-2872.
18. Wong-Berringer A, Hindler J, Loeloff M, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis. 2002; 34:135-146.
19. Tenover FC, Raney PM, Williams PP, et al. Evaluation of the NCCLS Extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during project ICARE. J Clin Microbiol. 2003; 41:3142-3146.
20. Overman SB, Shepherd S, Fountain E, Ribes JA. Difficulty in detection of extended spectrum beta-lactamases (ESBL) produced in the clinical microbiology laboratory. In: American Society for Microbiology 103rd General Meeting Abstracts. Washington, DC: American Society for Microbiology; 2003; C-263:167.
21. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2001; 45:3548-3554.